AD

'Love At First Swipe' win legal dispute against Tinder owners 'The Match Group'

Retrieved on: 
Wednesday, March 9, 2022
United Kingdom, Match Group, FIRST, Hearing, LOVE, Term of patent, Love, Woman, HGF, App, UKIPO, LAFS, CEO, AD, Application, Video game, Match, Tinder

The legal victory comes after a two year struggle with the Goliath Match Group, and owner of Tinder, who objected to the Manchester based dating App's UK trade mark application to register, 'Love At First Swipe'.

Key Points: 
  • The legal victory comes after a two year struggle with the Goliath Match Group, and owner of Tinder, who objected to the Manchester based dating App's UK trade mark application to register, 'Love At First Swipe'.
  • On 14th January 2022, the United Kingdom Intellectual Property Office ('UKIPO') rejected Match's opposition, crucially allowing LAFS's Application to proceed for dating apps and dating services.
  • The UKIPO held that LAFS's app and dating service LOVE AT FIRST SWIPE would not be confused or linked to Match as a result.
  • HGF's Lee Curtis who represented LAFS at the UKIPO Hearing has been instrumental in this victory for the brand.

'Love At First Swipe' win legal dispute against Tinder owners 'The Match Group'

Retrieved on: 
Wednesday, March 9, 2022
United Kingdom, Match Group, Application, FIRST, Hearing, LOVE, Multimedia, Term of patent, Love, Woman, HGF, App, UKIPO, LAFS, CEO, AD, View, Public relations, Match, Tinder

The legal victory comes after a two year struggle with the Goliath Match Group, and owner of Tinder, who objected to the Manchester based dating App's UK trade mark application to register, 'Love At First Swipe'.

Key Points: 
  • The legal victory comes after a two year struggle with the Goliath Match Group, and owner of Tinder, who objected to the Manchester based dating App's UK trade mark application to register, 'Love At First Swipe'.
  • On 14th January 2022, the United Kingdom Intellectual Property Office ('UKIPO') rejected Match's opposition, crucially allowing LAFS's Application to proceed for dating apps and dating services.
  • The UKIPO held that LAFS's app and dating service LOVE AT FIRST SWIPE would not be confused or linked to Match as a result.
  • HGF's Lee Curtis who represented LAFS at the UKIPO Hearing has been instrumental in this victory for the brand.

LeddarTech Announces the Appointment of Derek Aberle and Nick Stone to Its Board of Directors

Retrieved on: 
Wednesday, March 9, 2022
Tata Motors, Leddar, University, Business Development Bank of Canada, Level 2, Wireless, XLrator Media, Lidar, Texas Instruments, TPG Capital, Growth, ADAS, University of San Diego School of Law, Stanford Graduate School of Business, LinkedIn, Industry, Morgan Stanley, Business, Name, Facebook, Velodyne Lidar, Director, Economics, NXP, Artificial intelligence, GLOBE, IP, CEO, AD, EVP, Leadership, BMW, University of California, Santa Cruz Silicon Valley Initiatives, Knowledge, Alliance, Tier, Twitter, Investment, Board, Acquisition, Board of directors, GM, Perception, Chief executive officer, Group, Technology, Harvard University, YouTube, Management, Qualcomm

Mr. Derek Aberles experience includes senior executive roles in large, global technology companies as well as the investment community.

Key Points: 
  • Mr. Derek Aberles experience includes senior executive roles in large, global technology companies as well as the investment community.
  • Mr. Aberle led many of Qualcomms global growth initiatives, including in markets beyond smartphones as well as its expansion in China.
  • I am very proud to welcome Derek and Nick, stated Mr. Michel Brl, Chairman of the Board of Directors of LeddarTech.
  • We are privileged to welcome Derek and Nick to our Board, stated Mr. Charles Boulanger, CEO of LeddarTech.

Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022

Retrieved on: 
Tuesday, March 8, 2022
PD, Amnesia, Patient, Forward-looking statement, AD, Twitter, Security (finance), Dementia, Alzheimer's disease, Annual report, U.S. Securities and Exchange Commission, LinkedIn, Parkinson's disease, Company, Axonal transport, Down syndrome, Neurodegeneration, Risk

Presentation will Showcase Trial Design in Upcoming Phase 3 Trial in Parkinson's Disease

Key Points: 
  • Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .
  • Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.
  • Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Renesas Unveils R-Car V4H for Automated Driving Level 2+ / Level 3 to Support High-Volume Vehicle Production in 2024

Retrieved on: 
Tuesday, March 8, 2022
Software, Internet, Hardware, Automotive, Consumer Electronics, Technology, General Automotive, Semiconductor, Cortex, YouTube, ReMarkable, ADAS, NCAP, HW, TSE, Deep learning, Machine learning, AD, GFLOPS, Twitter, GPU, Safety, Infrastructure, SOC, LinkedIn, Instagram, Solution, GHZ, Renesas Electronics, Multimedia, Efficiency, IP, ASIL, Compliance, Écu, SDK, Electronics Corporation of India Limited, Radar, ASIL D, BOM, Arm Ltd., CNN, IOT, Mobile phone, Video game console, EU, Facebook

It targets the highest volume zones of automated driving: Level 2+ and Level 3.

Key Points: 
  • It targets the highest volume zones of automated driving: Level 2+ and Level 3.
  • Thanks to a high level of integration, the R-Car V4H allows customers to develop cost-competitive, single-chip, ADAS electric control units (ECUs).
  • These control units may support driving systems appropriate for automated driving Levels 2+ and Level 3, including full NCAP 2025 features.
  • As Renesas expands its scalable R-Car portfolio, we expect to see cutting-edge ADAS adopted in all vehicle types, from mid-range to entry-level.

Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease at AD/PD and NDDS Scientific Conferences

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Risk, NDA, Diagnosis, Neurotoxicity, Ageing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Oral, Reverse-path forwarding, Plasma, Biomarker, Science, AD, Food, Alzheimer's disease, Doctor of Philosophy, Safety, Lists of diseases, Neurodegeneration, Cerebral edema, Program, New Drug Application, Precision medicine, Plaque, Fast Track, Disease, Conference, CEO, Maintenance, National Institute, National Institute on Aging, Technology, Brain, International Conference on Emerging Infectious Diseases, MD, Pathology, Pharmaceutical industry, Medical imaging, Alzheon, APOE4

This oral presentation will be included in the Scientific Symposium: APOE Mechanisms and Treatment Strategies and can be accessed through the conference virtual portal or directly onsite.

Key Points: 
  • This oral presentation will be included in the Scientific Symposium: APOE Mechanisms and Treatment Strategies and can be accessed through the conference virtual portal or directly onsite.
  • At the NDDS conference, Dr. John Hey, Chief Scientific Officer of Alzheon and Alzheon CEO, Dr. Martin Tolar will give oral presentations on Tuesday, March 29, 2022, at 12:30 p.m.
  • This is a double-blind, randomized trial comparing one dose of oral ALZ-801 to placebo treatment over 78 weeks.
  • Our lead Alzheimers clinical candidate, ALZ-801 , is an oral agent in Phase 3 development as a potentially disease modifying treatment for AD.

Excited with PMI Chicagoland Chapter's 1st Annual Agile Conference

Retrieved on: 
Monday, March 7, 2022
Microsoft, Poor Unfortunate Souls, Disciplined agile delivery, AM, Lewis University, Consultant, Project Management Institute, Project management, PMI, AD, Agile, Business agility, Three pillars, Program, DA, Catholic (term), The Oregon Trail 3rd Edition, Leadership, Conference, Book, ALM, Object, All the Right Reasons, CEC, Association, CAL, Transformation, Choose Your Weapon, Chapter, Management, Medicine, Agility

Register to attend via this link: 2022 Agile Conference

Key Points: 
  • Register to attend via this link: 2022 Agile Conference
    Opening Keynote "You might just be an Agile Leader if" will be presented by Bob Galen, an Agile Practitioner, Trainer & Coach.
  • In this role, he helps guide companies and teams in their pragmatic adoption and organizational shift towards agile methods of working.
  • He is a Certified Enterprise Coach (CEC), CAL I trainer, and an active member of the Agile & Scrum Alliances.
  • He is also co-creator of the Disciplined Agile (DA) tool kit as well as the Agile Modeling (AM) and Agile Data (AD) methodologies.

Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Thursday, March 3, 2022
Gian Maria Annovi, PD, Amnesia, Patient, Forward-looking statement, AD, Twitter, Neurodegeneration, Dementia, Alzheimer's disease, Annual report, Security (finance), U.S. Securities and Exchange Commission, LinkedIn, Parkinson's disease, NYSE, Webcast, Company, Axonal transport, Conference, Down syndrome, Risk, Pharmaceutical industry

Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.

Key Points: 
  • Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.
  • For more information on Annovis Bio, please visit the company's website www.annovisbio.com and follow us on LinkedIn , and Twitter .
  • Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.
  • Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

Retrieved on: 
Friday, March 4, 2022
Accelerated approval (FDA), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, MHLW, Research, MCI, AD, Food, Biologics license application, PMDA, Ministry, BAN2401, Medicines and Healthcare products Regulatory Agency, FDA, Person, Ministry of Health, Labour and Welfare, Alzheimer's disease, Disease, Trial of the century, Marketing, Medication, Clarity, Amyloid beta, Review, Ministry of Health (Saudi Arabia), Pharmaceuticals and Medical Devices Agency, Pharmaceutical industry, Biogen, Eisai, Health

By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.

Key Points: 
  • By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.
  • The prior assessment consultation is conducted at the development stage before new drug application submission based on available quality, non-clinical and clinical data.
  • By identifying and resolving any potential issues prior to submission, the aim is to shorten application review time.
  • Lecanemab is an investigational humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic.

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease

Retrieved on: 
Saturday, March 5, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibrosis, Center for Drug Evaluation and Research, Patient, Clinical trial, CDE, NMPA, MOA, AD, Risk, Food, Antibody, Biotechnology, Safety, News, Inflammation, FDA, Therapy, Euronext Amsterdam, Plaque, HKEX, Fast Track, Company, Cancer, QPCT, Alzheimer's disease, Center, Medicine, Trial of the century, Judgement, National Medical Products Administration, Autoimmune disease, CCL2, Protein, Neuroinflammation, Brain, Partnership, Management, Pathology, Pharmaceutical industry, Medical imaging, Risk management, EU, Amyloid beta, Simcere Pharmaceutical, Varoglutamstat (PQ912, SIM0408), Vivoryon Therapeutics N.V., Simcere Pharmaceutical Group, VAROGLUTAMSTAT (PQ912, SIM0408), VIVORYON THERAPEUTICS N.V., SIMCERE PHARMACEUTICAL GROUP

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease (news with additional features)

Key Points: 
  • Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease (news with additional features)
    The issuer is solely responsible for the content of this announcement.
  • "We are proud to have obtained CDE approval of our Clinical Trial Application of varoglutamstat which represents our strong commitment in the battle against Alzheimer's disease," said Dr. Renhong Tang, Executive Vice President of Simcere.
  • Varoglutamstat is currently in Phase 2 clinical development in Europe (VIVIAD study) and the U.S. (VIVA-MIND study).
  • Simcere focuses on oncology, central nervous system disease and autoimmune disease therapeutic areas, with a diversified product portfolio and industry-leading capabilities.